-
1
-
-
0029044491
-
The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand
-
Chaney, S. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (Review). Int. J. Oncol., 6: 1291-1305, 1995.
-
(1995)
Int. J. Oncol.
, vol.6
, pp. 1291-1305
-
-
Chaney, S.1
-
2
-
-
0017061157
-
Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers
-
Kidani, Y., Inagaki, K., and Tsugagoshi, S. Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers. Gann, 67: 921-922, 1976.
-
(1976)
Gann
, vol.67
, pp. 921-922
-
-
Kidani, Y.1
Inagaki, K.2
Tsugagoshi, S.3
-
3
-
-
0018245944
-
Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascite form
-
Kidani, Y., Inagaki, K., Ligo, M., Hoshi, A., and Kuretani, K. Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascite form. J. Med. Chem., 21: 1315-1318, 1978.
-
(1978)
J. Med. Chem.
, vol.21
, pp. 1315-1318
-
-
Kidani, Y.1
Inagaki, K.2
Ligo, M.3
Hoshi, A.4
Kuretani, K.5
-
4
-
-
0028339337
-
Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes
-
Siddik, Z. H., al-Baker, S., Thai, G., and Khokhar, A. R. Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes. J. Cancer Res. Clin. Oncol., 120: 409-414, 1994.
-
(1994)
J. Cancer Res. Clin. Oncol.
, vol.120
, pp. 409-414
-
-
Siddik, Z.H.1
Al-Baker, S.2
Thai, G.3
Khokhar, A.R.4
-
5
-
-
0000525677
-
Comparison of an oxaliplatin-Taxol versus a carboplatin-Taxol regimen in the treatment of the MV-522 human lung tumor xenografts
-
Skou, G., Mangold, G., Dexter, D., and Von Hoff, D. Comparison of an oxaliplatin-Taxol versus a carboplatin-Taxol regimen in the treatment of the MV-522 human lung tumor xenografts. Proc. Am. Assoc. Cancer Res., 37: 375, 1996.
-
(1996)
Proc. Am. Assoc. Cancer Res.
, vol.37
, pp. 375
-
-
Skou, G.1
Mangold, G.2
Dexter, D.3
Von Hoff, D.4
-
6
-
-
0030722949
-
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidase synthase inhibitor AG337 in human colon, breast, and ovarian cancers
-
Raymond, E., Buquet-Fagot, Djelloul, C., J., Mester, E., Cvitkovic, C., Louvet, C., and Gespach, C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidase synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anticancer Drugs, 8: 876-885, 1997.
-
(1997)
Anticancer Drugs
, vol.8
, pp. 876-885
-
-
Raymond, E.1
Buquet-Fagot2
Djelloul, C.J.3
Mester, E.4
Cvitkovic, C.5
Louvet, C.6
Gespach, C.7
-
7
-
-
0001670580
-
Report on the pharmacokinetic of oxaliplatin in patients with normal and impaired renal function
-
Bastian, G. Report on the pharmacokinetic of oxaliplatin in patients with normal and impaired renal function. Ann. Oncol., 5: 126, 1994.
-
(1994)
Ann. Oncol.
, vol.5
, pp. 126
-
-
Bastian, G.1
-
8
-
-
0025020085
-
Phase I study of oxaliplatin in patients with advanced cancer
-
Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L., and Marty, M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol., 25: 299-303, 1990.
-
(1990)
Cancer Chemother. Pharmacol.
, vol.25
, pp. 299-303
-
-
Extra, J.M.1
Espie, M.2
Calvo, F.3
Ferme, C.4
Mignot, L.5
Marty, M.6
-
9
-
-
0027522684
-
Role of carrier ligand in platinum resistance of human carcinoma cell lines
-
Schmidt, W., and Chaney, S. G. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res., 53: 799-805, 1993.
-
(1993)
Cancer Res.
, vol.53
, pp. 799-805
-
-
Schmidt, W.1
Chaney, S.G.2
-
10
-
-
0030480849
-
Increased gene specific repair of cisplatin induced inter-strand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity
-
Lond.
-
Petersen, L. N., Mamenta, E. L., Stevnsner, T., Chaney, S. G., and Bohr, V. A. Increased gene specific repair of cisplatin induced inter-strand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Carcinogenesis (Lond.), 17: 2597-2602, 1996.
-
(1996)
Carcinogenesis
, vol.17
, pp. 2597-2602
-
-
Petersen, L.N.1
Mamenta, E.L.2
Stevnsner, T.3
Chaney, S.G.4
Bohr, V.A.5
-
11
-
-
0028304413
-
Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines
-
Mamenta, E. L., Poma, E. E., Kaufmann, W. K., Delmastro, D. A., Grady, H. L., and Chaney, S. G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 54: 3500-3505, 1994.
-
(1994)
Cancer Res.
, vol.54
, pp. 3500-3505
-
-
Mamenta, E.L.1
Poma, E.E.2
Kaufmann, W.K.3
Delmastro, D.A.4
Grady, H.L.5
Chaney, S.G.6
-
12
-
-
0000460127
-
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel
-
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., and Fojo, T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol., 52: 1855-1865, 1996.
-
(1996)
Biochem. Pharmacol.
, vol.52
, pp. 1855-1865
-
-
Rixe, O.1
Ortuzar, W.2
Alvarez, M.3
Parker, R.4
Reed, E.5
Paull, K.6
Fojo, T.7
-
13
-
-
0025017307
-
Effects of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality
-
Page, J. D., Husain, I., Sancar, A., and Chaney, S. G. Effects of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry, 29: 1016-1024, 1990.
-
(1990)
Biochemistry
, vol.29
, pp. 1016-1024
-
-
Page, J.D.1
Husain, I.2
Sancar, A.3
Chaney, S.G.4
-
14
-
-
0001377795
-
The crystal structure and absolute configurations of the antitumor complexes Pt(oxalato)(1R,2R-cyclohexanediamine) and Pt(malanato)(1R,2R-cyclohexanediamine)
-
Bruk, M. A., Bau, R., Noji, M., Inagaki, K., and Kidani, Y. The crystal structure and absolute configurations of the antitumor complexes Pt(oxalato)(1R,2R-cyclohexanediamine) and Pt(malanato)(1R,2R-cyclohexanediamine). Inorg. Chem. Acta, 92: 279-284, 1984.
-
(1984)
Inorg. Chem. Acta
, vol.92
, pp. 279-284
-
-
Bruk, M.A.1
Bau, R.2
Noji, M.3
Inagaki, K.4
Kidani, Y.5
-
15
-
-
0002989164
-
Tris-[cis-dichloro(1,2-diaminocyclohexane)platinum(II)] hydrate and cis-dibromo(1,2-diaminocyclohexane)platinum(II)
-
Lock, C. J. L., and Pilon, P. Tris-[cis-dichloro(1,2-diaminocyclohexane)platinum(II)] hydrate and cis-dibromo(1,2-diaminocyclohexane)platinum(II). Acta Crystallogr. Sect. B Struct. Sci., B27: 45-49, 1981.
-
(1981)
Acta Crystallogr. Sect. B Struct. Sci.
, vol.B27
, pp. 45-49
-
-
Lock, C.J.L.1
Pilon, P.2
-
16
-
-
0029904811
-
The role of DNA mismatch repair in platinum drug resistance
-
Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
-
(1996)
Cancer Res.
, vol.56
, pp. 4881-4886
-
-
Fink, D.1
Nebel, S.2
Aebi, S.3
Zheng, H.4
Cenni, B.5
Nehme, A.6
Christen, R.D.7
Howell, S.B.8
-
17
-
-
0030967259
-
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients
-
Gamelin, E., Le Bouil, A., Boisdron-Celle, M., Turcant, A., Delva, R., Cailleux, A., Krikorian, A., Brienza, S., Cvitkovic, E., Robert, J., Larra, F., and Allain, P. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin. Cancer Res., 3: 891-899, 1997.
-
(1997)
Clin. Cancer Res.
, vol.3
, pp. 891-899
-
-
Gamelin, E.1
Le Bouil, A.2
Boisdron-Celle, M.3
Turcant, A.4
Delva, R.5
Cailleux, A.6
Krikorian, A.7
Brienza, S.8
Cvitkovic, E.9
Robert, J.10
Larra, F.11
Allain, P.12
-
18
-
-
0027146423
-
In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin
-
Pendyala, L., and Creaven, P. J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res., 53: 5970-5976, 1993.
-
(1993)
Cancer Res.
, vol.53
, pp. 5970-5976
-
-
Pendyala, L.1
Creaven, P.J.2
-
19
-
-
0028828382
-
Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers
-
Pendyala, L., Kidani, Y., Perez, R., Wilkes, J., Bernacki, R. J., and Creaven, P. J. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett., 97: 177-184, 1995.
-
(1995)
Cancer Lett.
, vol.97
, pp. 177-184
-
-
Pendyala, L.1
Kidani, Y.2
Perez, R.3
Wilkes, J.4
Bernacki, R.J.5
Creaven, P.J.6
-
20
-
-
0029968277
-
Role of chemotherapy for advanced colorectal cancer: New opportunities
-
Bleiberg, H. Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin. Oncol., 23: 42-50, 1996.
-
(1996)
Semin. Oncol.
, vol.23
, pp. 42-50
-
-
Bleiberg, H.1
-
21
-
-
0030888321
-
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
-
de Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., Andre, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., and Krulik, M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214-219, 1997.
-
(1997)
Eur. J. Cancer
, vol.33
, pp. 214-219
-
-
De Gramont, A.1
Vignoud, J.2
Tournigand, C.3
Louvet, C.4
Andre, T.5
Varette, C.6
Raymond, E.7
Moreau, S.8
Le Bail, N.9
Krulik, M.10
-
22
-
-
0027310715
-
Oxaliplatin activity against metastatic colorectal cancer: A Phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
-
Levi, F., Perpoint, B., Garufi, C., Focan, C., Chollet, P., Depres-Brummer, P., Zidani, R., Brienza, S., Itzhaki, M., Iacobelli, S., et al. Oxaliplatin activity against metastatic colorectal cancer: a Phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer, 9: 1280-1284, 1993.
-
(1993)
Eur. J. Cancer
, vol.9
, pp. 1280-1284
-
-
Levi, F.1
Perpoint, B.2
Garufi, C.3
Focan, C.4
Chollet, P.5
Depres-Brummer, P.6
Zidani, R.7
Brienza, S.8
Itzhaki, M.9
Iacobelli, S.10
-
23
-
-
0001704607
-
Oxaliplatin (I-OHP) as first line chemotherapy in metastatic colorectal cancer (MCRC) patients: Preliminary activity/toxicity report
-
Becouarn, Y., Ychou, M., Ducreux, M., Borel, C., Bertheault-Cvitkovic, F., Seitz, J. F., Nasca, S., Rougier, P., Nguyen, T. D., Paillot, B., Raoul, J. L., and Fandi, A. Oxaliplatin (I-OHP) as first line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 229, 1997.
-
(1997)
Proc. Am. Soc. Clin. Oncol. Annu. Meet.
, vol.16
, pp. 229
-
-
Becouarn, Y.1
Ychou, M.2
Ducreux, M.3
Borel, C.4
Bertheault-Cvitkovic, F.5
Seitz, J.F.6
Nasca, S.7
Rougier, P.8
Nguyen, T.D.9
Paillot, B.10
Raoul, J.L.11
Fandi, A.12
-
24
-
-
0012797224
-
Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
-
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J. J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., Abad, A., Francois, E., Gamelin, E., Marty, M., Sastre, J., Seitz, J. F., and Ychou, M. Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol., 7: 95-98, 1996.
-
(1996)
Ann. Oncol.
, vol.7
, pp. 95-98
-
-
Machover, D.1
Diaz-Rubio, E.2
De Gramont, A.3
Schilf, A.4
Gastiaburu, J.J.5
Brienza, S.6
Itzhaki, M.7
Metzger, G.8
N'Daw, D.9
Vignoud, J.10
Abad, A.11
Francois, E.12
Gamelin, E.13
Marty, M.14
Sastre, J.15
Seitz, J.F.16
Ychou, M.17
-
25
-
-
0008468046
-
Oxaliplatin (1-OHP) synergistic clinical activity with 5-fluorouracil (FU) in FU-resistant colorectal cancer (CRC) patients (pts) is independent of FU +/- Folinic acid (FA)
-
Bleiberg, H., Gamelin, E., Francois, E., Andre, T., Extra, J. M., Nole, F., Bensmaine, M. A., Itzhaki, M., Brienza, S., and Cvitkovic, E. Oxaliplatin (1-OHP) synergistic clinical activity with 5-fluorouracil (FU) in FU-resistant colorectal cancer (CRC) patients (pts) is independent of FU +/-folinic acid (FA). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 206, 1996.
-
(1996)
Proc. Am. Soc. Clin. Oncol. Annu. Meet.
, vol.16
, pp. 206
-
-
Bleiberg, H.1
Gamelin, E.2
Francois, E.3
Andre, T.4
Extra, J.M.5
Nole, F.6
Bensmaine, M.A.7
Itzhaki, M.8
Brienza, S.9
Cvitkovic, E.10
-
26
-
-
0025051987
-
Selection of cancer chemotherapy for patient by an in vitro assay versus a clinician
-
Von Hoff, D., Sandbach, J., Clark, G., Turner, J., Forseth, B., Piccart, M., Colombo, N., and Muggia, F. Selection of cancer chemotherapy for patient by an in vitro assay versus a clinician. J. Natl. Cancer Inst., 82: 110-116, 1990.
-
(1990)
J. Natl. Cancer Inst.
, vol.82
, pp. 110-116
-
-
Von Hoff, D.1
Sandbach, J.2
Clark, G.3
Turner, J.4
Forseth, B.5
Piccart, M.6
Colombo, N.7
Muggia, F.8
-
27
-
-
0020597149
-
Prospective clinical trial of human tumor cloning system
-
Von Hoff, D., Clark, G., Stogdill, B., Sarosdy, M., O'Brien, M., Casper, T., Mattox, D., Page, C., Cruz, A., and Sandbach, J. Prospective clinical trial of human tumor cloning system. Cancer Res., 43: 1926-1931, 1983.
-
(1983)
Cancer Res.
, vol.43
, pp. 1926-1931
-
-
Von Hoff, D.1
Clark, G.2
Stogdill, B.3
Sarosdy, M.4
O'Brien, M.5
Casper, T.6
Mattox, D.7
Page, C.8
Cruz, A.9
Sandbach, J.10
-
29
-
-
0022263270
-
Antitumor activity of 1-OHP in mice
-
Mathe, G., Kidani, Y., Noji, M., Maral, R., Bourut, C., and Chenu, E. Antitumor activity of 1-OHP in mice. Cancer Lett., 27: 135-143, 1985.
-
(1985)
Cancer Lett.
, vol.27
, pp. 135-143
-
-
Mathe, G.1
Kidani, Y.2
Noji, M.3
Maral, R.4
Bourut, C.5
Chenu, E.6
-
30
-
-
0024373787
-
Antitumor activity of a new platinum complex oxalato (trans-l-1,2-diaminocyclohexane)platinum(II): New experimental data
-
Tashiro, T., Kawada, Y., Sakurai, Y., and Kidani, Y. Antitumor activity of a new platinum complex oxalato (trans-l-1,2-diaminocyclohexane)platinum(II): new experimental data. Biomed. Pharmacother., 43: 251-260, 1989.
-
(1989)
Biomed. Pharmacother.
, vol.43
, pp. 251-260
-
-
Tashiro, T.1
Kawada, Y.2
Sakurai, Y.3
Kidani, Y.4
-
31
-
-
0024407292
-
Oxalato-platinum or l-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
-
Mathe, G., Kidani, Y., Segiguchi, M., Edguchi, M., Fredj, G., Peytavin, G., Misset, J. L., Brienza, S., de Vassal, F., and Chenu, E. Oxalato-platinum or l-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother., 43: 237-250, 1989.
-
(1989)
Biomed. Pharmacother.
, vol.43
, pp. 237-250
-
-
Mathe, G.1
Kidani, Y.2
Segiguchi, M.3
Edguchi, M.4
Fredj, G.5
Peytavin, G.6
Misset, J.L.7
Brienza, S.8
De Vassal, F.9
Chenu, E.10
-
32
-
-
0017386903
-
Synthesis and anti-tumor activities of platinum (II) complexes of 1,2-diaminocyclohexane isomers and their related activities
-
Kidani, Y., Inagaki, K., Saito, R., and Tsukagshi, S. Synthesis and anti-tumor activities of platinum (II) complexes of 1,2-diaminocyclohexane isomers and their related activities. J. Clin. Haematol. Oncol., 7: 197-209, 1977.
-
(1977)
J. Clin. Haematol. Oncol.
, vol.7
, pp. 197-209
-
-
Kidani, Y.1
Inagaki, K.2
Saito, R.3
Tsukagshi, S.4
-
33
-
-
0029968277
-
Role of chemotherapy for advanced colorectal cancer: New opportunities
-
Bleiberg, H. Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin. Oncol., 23: 42-50, 1996.
-
(1996)
Semin. Oncol.
, vol.23
, pp. 42-50
-
-
Bleiberg, H.1
-
34
-
-
0025338285
-
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate
-
Caussanel, J. P., Levi, F., Brienza, S., Misset, J. L., Itzhaki, M., Adam, R., Milano, G., Hecquet, B., and Mathe, G. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl. Cancer Inst., 82: 1046-1050, 1990.
-
(1990)
J. Natl. Cancer Inst.
, vol.82
, pp. 1046-1050
-
-
Caussanel, J.P.1
Levi, F.2
Brienza, S.3
Misset, J.L.4
Itzhaki, M.5
Adam, R.6
Milano, G.7
Hecquet, B.8
Mathe, G.9
-
35
-
-
0029056498
-
Intracellular glutathione and cytotoxicity of platinum complexes
-
Pendyala, L., Creaven, P. J., Perez, R., Zdanowicz, J. R., and Raghavan, D. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother. Pharmacol., 36: 271-278, 1995.
-
(1995)
Cancer Chemother. Pharmacol.
, vol.36
, pp. 271-278
-
-
Pendyala, L.1
Creaven, P.J.2
Perez, R.3
Zdanowicz, J.R.4
Raghavan, D.5
-
36
-
-
8944230189
-
Loss of DNA mismatch repair in acquired resistance to cisplatin
-
Aebi, S., Kurdihaidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., and Fishel, R. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 5: 3087-3090, 1996.
-
(1996)
Cancer Res.
, vol.5
, pp. 3087-3090
-
-
Aebi, S.1
Kurdihaidar, B.2
Gordon, R.3
Cenni, B.4
Zheng, H.5
Fink, D.6
Christen, R.D.7
Boland, C.R.8
Koi, M.9
Fishel, R.10
-
37
-
-
0030198880
-
The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin
-
Mello, J. A., Acharya, S., Fishel, R., and Essigann, J. M. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem. Biol., 3: 579-589, 1996.
-
(1996)
Chem. Biol.
, vol.3
, pp. 579-589
-
-
Mello, J.A.1
Acharya, S.2
Fishel, R.3
Essigann, J.M.4
-
38
-
-
0029665878
-
4-methylthymine or the cisplatin-d(GpG) adduct
-
4-methylthymine or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA, 93: 6443-6447, 1996.
-
(1996)
Proc. Natl. Acad. Sci. USA
, vol.93
, pp. 6443-6447
-
-
Duckett, D.R.1
Drummond, J.T.2
Murchie, A.I.H.3
Reardon, J.T.4
Sancar, A.5
Lilley, D.M.J.6
Modrich, P.7
|